Skip to main content

Search

Study Title Study Sponsor Status Study Drug Trial Phase Study Protocol Number Site
Efficacy Of Single Dose Rituximab and Mycophenolate Versus Two Doses Rituximab in Children with Steroid Dependent and Frequent Relapsing Nephrotic Syndrome: Randomized Open-Labeled Pilot Trial King Faisal Specialist Hospital and Research Center Ongoing Rituximab / Mycophenolate 2 2020-99 King Faisal Specialist Hospital and Research Center (Jeddah)
A Prospective Phase II study utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients with Advanced Colorectal Cancer KAIMRC Ongoing PANITUMUMAB - cetuximab 2 RC20/170/R King Abdulaziz Medical City NG (Riyadh)
Deferoxamine management protocol in COVID-19 patients King Saud Medical City Ongoing Deferoxamine 2 20082103 King Saud Medical City (Riyadh)
A global multicenter,randomized,double-blind,placebo -controlled, adaptive designed phase Ⅲ clinical trial to evaluate the efficacy, safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in adults 18 years old and above MOH / CanSino Rejected Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 3 CS-CTP-AD5NCOV-ⅢCo King Fahad Medical City (Riyadh)
A phase III randomized clinical trial comparing post-transplant cyclophosphamide with calcineurin inhibitors as a GVHD prophylaxis to standard care of methotrexate and calcineurin inhibitors for acute leukemia incorporating patient pharmacogenomic profiling – a personalized medicine approach in allogeneic hematopoietic cell transplantation PMAT King Faisal Specialist Hospital and Research Centre Ongoing CYCLOPHOSPHAMIDE (ENDOXAN) 3 1- 28/05/2019 KFSH & RC-R
Phase 2, Multi-Center, Double-Blind, Randomized, 2-Arm, Parallel Study to Assess the Efficacy and Safety of Ryanodex (EGL-4104) as Adjuvant Treatment in Subjects with Exertional Heat Stroke (EHS) Eagle Pharmaceuticals Ongoing Dantrolene 2 EGL-4104-C-1801 Mina Al-Shari' Al-Jadid Hospital
An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose-titration Study Followed by a Fixed-dose Observation Period to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children and Adolescents from 5 to less than 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC) Astellas Rejected Mirabegron 3 178-CL-206A King Abdulaziz University Hospital (Jeddah)
Vitamin D Status Correction and Validation of its Potential Clinical Utility through Discovery Proteomic Analysis Prince Mutaib Chair for Biomarkers of Osteoporosis/synergypha-rma Completed cholecalciferol 3 E-15-1667 KKUH
Vitamin D status and Covid-19 in Saudi Settings: A randomized open-label study on the possible role of vitamin D on improving clinical outcomes KKUH Ongoing VITA-D 3 H-01-R-012 King Fahad Medical City (Riyadh)
Vitamin C as a potential ameliorating agent against hepatotoxicity among alcoholic abusers Qassim University Completed Vitamin C (ascorbic acid ) Cevital 3 20111803 Mental Health Hospital (Abha)
View 181 - 190 From 774